Core Viewpoint - Qianjin Pharmaceutical (600479) confirmed that during the transition period of its acquisition plan, any profits or increases in net assets from the target company will be enjoyed by the listed company [1] Group 1 - The company responded to investor inquiries on an interactive platform regarding its acquisition plan [1] - The increase in investment income for the company in the third quarter was attributed to the investment returns from its stake in the Guohai Guochuang Pharmaceutical Fund [1]